Rapid Therapeutic Science Laboratories, Inc is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company is also focusing on manufacturing its own branded metered dose inhaler (MDI) under the inhaler brand name.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets 12:10:58 2026-08-21 pm EDT			5-day change	1st Jan Change
0.000400 ^USD	+300.00%		-.--%	-73.33%

23-08-14	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-05-12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Market Cap	85.73K 76.92K 71.11K 64.41K 120K 8.17M 122K 850K 339K 4.27M 322K 315K 13.56M	P/E 2021	-16.6x	P/E 2022	-3.24x
Enterprise Value	3.92M 3.51M 3.25M 2.94M 5.5M 373M 5.56M 38.84M 15.47M 195M 14.7M 14.39M 620M	EV / Sales 2021	93,978,853,933x	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

23-08-14	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-05-12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-03-30	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-29	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
22-11-10	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-08-12	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
22-05-30	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	CI
22-05-11	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-03-16	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-03-15	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
22-01-27	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding	CI
22-01-17	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC	CI
21-11-11	Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex	CI

23-12-06	Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K	PU
23-03-30	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
23-03-21	White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy	AQ
22-12-13	Rapid Therapeutic Science Laboratories Updates Patents	AQ
22-11-10	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

Rapid Therapeutic Science Laboratories, Inc. Stock

Stocks

RTSL

US7534312043

Pharmaceuticals

Valuation: Rapid Therapeutic Science Laboratories, Inc.

Chart: Rapid Therapeutic Science Laboratories, Inc.

Latest news: Rapid Therapeutic Science Laboratories, Inc.

Press Releases: Rapid Therapeutic Science Laboratories, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Rapid Therapeutic Science Laboratories, Inc.

Latest insider transactions

Alternative Medicine

Financials

Company Profile

Quotes

1 day	+300.00%
3 months	+300.00%
6 months	-93.33%
Current year	-73.33%

Current year	0		0.01
1 year	0		0.01
3 years	0		0.01
5 years	0		12.5
10 years	0		125

Manager	Title	Age	Since
Donal Schmidt CEO	Chief Executive Officer	65	2019-11-14
D. Watler DFI	Director of Finance/CFO	77	2019-11-14

Director	Title	Age	Since
D. Watler BRD	Director/Board Member	77	2019-11-14
Donal Schmidt BRD	Director/Board Member	65	2019-11-14

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/27/21	Sean Berrier	Don	Executive/Senior Manager	2,000,000	1.0332%
12/27/21	Texas Mdi, Inc.	Don	Company	2,000,000	1.0332%
8/27/21	Henry Punzi	Other	Director	125,000	0.0646%

	2021	2022
Net sales	0 0 0 0 0 0.05 0 0.01 0 0.03 0 0 0.08	-
Net income	-2.87M -2.57M -2.38M -2.15M -4.03M -273M -4.07M -28.44M -11.33M -143M -10.76M -10.53M -454M	-1.79M -1.61M -1.49M -1.35M -2.52M -171M -2.55M -17.8M -7.09M -89.44M -6.73M -6.59M -284M
Net Debt	1.79M 1.61M 1.49M 1.35M 2.52M 171M 2.55M 17.78M 7.08M 89.36M 6.73M 6.59M 284M	3.83M 3.44M 3.18M 2.88M 5.38M 365M 5.44M 37.99M 15.13M 191M 14.38M 14.07M 606M

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.	+300.00%	-.--%	-82.61%	-91.49%	7.59K
ELI LILLY AND COMPANY	+0.50%	+1.38%	+57.09%	+129.96%	1,148B
JOHNSON & JOHNSON	+0.86%	+5.14%	+45.00%	+86.15%	652B
ABBVIE INC.	-0.14%	+0.42%	+25.69%	+105.85%	505B
ROCHE HOLDING AG	-0.05%	+1.73%	+52.74%	+67.74%	384B
MERCK & CO., INC.	-0.63%	-5.97%	+61.93%	+37.06%	348B
NOVARTIS AG	+0.34%	+1.84%	+30.70%	+54.27%	294B
ASTRAZENECA PLC	-0.45%	+1.19%	+2.89%	+26.08%	264B
AMGEN INC.	+0.87%	+3.08%	+54.69%	+72.74%	244B
GILEAD SCIENCES, INC.	+0.08%	+3.67%	+35.05%	+107.78%	197B
Average	+30.14%	+1.25%	+28.32%	+59.61%	403.72B
Weighted average by Cap.	+0.26%	+1.50%	+44.52%	+89.10%